amorchem header logo close button Menu
arrow leftBack to portfolio

Kallikrein

Kallikrein is a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.

The project was initiated in partnership with a group of scientists from Sinai Health’s Lunenfeld-Tanenbaum Research Institute (LTRI) in Toronto, Canada and focuses on a specific group of enzymes called tissue kallikreins. These proteins play a critical role in development of  Netherton Syndrome and other skin inflammatory diseases. In 2018, TIAP and Evotec, through their drug discovery acceleration platform LAB150, provided funding, medicinal chemistry expertise, project management and business development support to advance initial efforts. The novel kallikrein-focused approach holds promise for treating Netherton Syndrome and, more broadly, atopic inflammatory dermatitis.